Abstract
ObjectiveThis study was designed to assess the level of uptake of human papillomavirus (HPV) vaccination and its associated factors among school-age adolescent girls.DesignSchool-based cross-sectional study.SettingHigh schools in Mettu town, southwest Ethiopia, from 5 February to 10 March 2022.ParticipantsData were collected using a pretested and structured questionnaire through face-to-face interviews with 667 adolescent girls selected via multistage random sampling. Data were entered into EpiData V.3.1 and exported to SPSS V.26 for analysis. Simple binary logistic regression was done, and variables with a p value less than 0.25 were entered into a multivariable logistic regression model; variables with a p value <0.05 were considered significant.ResultsAbout half (48.6%) of adolescent girls aged 14–18 years had received the HPV vaccine. Being in the 16–18 years age group (adjusted OR 2.7, 95% CI 1.50 to 4.80), having good knowledge (2.14, 95% CI 1.29 to 3.52), having a positive attitude (5.86, 95% CI 3.51 to 9.76), and getting encouragement from healthcare workers (3.04, 95% CI 1.36 to 6.79), teachers (2.14, 95% CI 1.05 to 4.34) and parents (2.39, 95% CI 1.02 to 5.64) were significantly associated with vaccine uptake.ConclusionThe uptake of HPV vaccination was low. Having good knowledge and positive attitude as well as encouragement from parents, healthcare workers and teachers were identified as factors associated with HPV vaccine uptake. Improving knowledge about HPV and involving teachers and parents in the immunisation campaign might help promote HPV vaccine uptake.
Reference45 articles.
1. Wang J , Tang D , Wang K , et al . HPV genotype prevalence and distribution during 2009 – 2018 in Xinjiang, China: baseline surveys prior to mass HPV vaccination. BMC Women’s Health 2019;19. doi:10.1186/s12905-019-0785-3
2. Bocquier A , Michel M , Giraudeau B , et al . Impact of a School- based and primary Care- based Multicomponent intervention on HPV vaccination coverage among French adolescents: a cluster randomised controlled trial protocol (the Prevhpv study). BMJ Open 2022;12:e057943. doi:10.1136/bmjopen-2021-057943
3. World Health Organization(WHO) . Guidelines to assure the quality, safety and efficacy of recombinant human Papillomavirus virus-like particle vaccines. 2016:51–113.
4. Human Papillomavirus in Ethiopia;Derbie;Virusdisease,2019
5. Mengesha A , Messele A , Beletew B . Knowledge and attitude towards Cervical cancer among reproductive age group women in Gondar town. BMC Public Health 2020;20. doi:10.1186/s12889-020-8229-4